VJHemOnc is committed to improving our service to you

EHA 2019 | JULIET: CRS and neurotoxicity in DLBCL

VJHemOnc is committed to improving our service to you

David Maloney

A post-hoc analysis of the JULIET trial (NCT02445248) is discussed by David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. The analysis investigated CRS and neurotoxicity in the treatment of adult relapsed or refractory diffuse large B-cell lymphoma (DLBCL) with CAR T-cell therapy. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter